3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine has been researched along with Candidiasis--Invasive* in 1 studies
1 other study(ies) available for 3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine and Candidiasis--Invasive
Article | Year |
---|---|
The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.
The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections. Topics: Aminopyridines; Animals; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Caspofungin; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Fluconazole; Isoxazoles; Lipopeptides; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2015 |